A unified sample preparation protocol for proteomic and genomic profiling of cervical swabs to identify biomarkers for cervical cancer screening

Cervical cancer screening is ideally suited for the development of biomarkers due to the ease of tissue acquisition and the well‐established histological transitions. Furthermore, cell and biologic fluid obtained from cervix samples undergo specific molecular changes that can be profiled. However, the ideal manner and techniques for preparing cervical samples remains to be determined. To address this critical issue a patient screening protein and nucleic acid collection protocol was established. RNAlater was used to collect the samples followed by proteomic methods to identify proteins that were differentially expressed in normal cervical epithelial versus cervical cancer cells. Three hundred ninety spots were identified via 2‐D DIGE that were expressed at either higher or lower levels (>three‐fold) in cervical cancer samples. These proteomic results were compared to genes in a cDNA microarray analysis of microdissected neoplastic cervical specimens to identify overlapping patterns of expression. The most frequent pathways represented by the combined dataset were: cell cycle: G2/M DNA damage checkpoint regulation; aryl hydrocarbon receptor signaling; p53 signaling; cell cycle: G1/S checkpoint regulation; and the ER stress pathway. HNRPA2B1 was identified as a biomarker candidate with increased expression in cancer compared to normal cervix and validated by Western blot.

[1]  T. Zhukov,et al.  Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  J. Rader,et al.  Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. , 2007, Cancer research.

[3]  J. Cobb,et al.  The murine plasma protein response to polymicrobial intra‐abdominal sepsis , 2007, Proteomics. Clinical applications.

[4]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[5]  J. Mulshine,et al.  Purification and Characterization of a Protein That Permits Early Detection of Lung Cancer , 1996, The Journal of Biological Chemistry.

[6]  H. Fujiki,et al.  Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia. , 2001, Cancer research.

[7]  Allen D. Delaney,et al.  Enabling Coupled Quantitative Genomics and Proteomics Analyses from Rat Spinal Cord Samples*S , 2007, Molecular & Cellular Proteomics.

[8]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[9]  N. Kiviat,et al.  Evaluation of a new p16INK4A ELISA test and a high‐risk HPV DNA test for cervical cancer screening: Results from proof‐of‐concept study , 2007 .

[10]  D. Malinowski.  Multiple biomarkers in molecular oncology. I. Molecular diagnostics applications in cervical cancer detection , 2007, Expert review of molecular diagnostics.

[11]  A. Shevchenko,et al.  Fast-response proteomics by accelerated in-gel digestion of proteins. , 2003, Analytical chemistry.

[12]  Wei Zhang,et al.  Increased yield of total RNA from fine-needle aspirates for use in expression microarray analysis. , 2002, BioTechniques.

[13]  Matthew Davison,et al.  Validation and development of fluorescence two‐dimensional differential gel electrophoresis proteomics technology , 2001, Proteomics.

[14]  S. Blacksell,et al.  The effect of sample degradation and RNA stabilization on classical swine fever virus RT-PCR and ELISA methods. , 2004, Journal of virological methods.

[15]  J. Cuzick,et al.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening , 2006, International journal of cancer.

[16]  Stephen O. David,et al.  A novel experimental design for comparative two‐dimensional gel analysis: Two‐dimensional difference gel electrophoresis incorporating a pooled internal standard , 2003, Proteomics.

[17]  A. van Dalen,et al.  Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin‐2 receptor α levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma , 2002, Cancer.

[18]  S. Anant,et al.  Expression of a novel regenerating gene product, Reg IV, by high density fermentation in Pichia pastoris: production, purification, and characterization. , 2003, Protein expression and purification.

[19]  K. Nakachi,et al.  Detection of plasma hnRNP B1 mRNA, a new cancer biomarker, in lung cancer patients by quantitative real-time polymerase chain reaction. , 2005, Lung cancer.

[20]  Zhihua Liu,et al.  Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray , 2004, Oncogene.

[21]  M. Ünlü,et al.  Difference gel electrophoresis. A single gel method for detecting changes in protein extracts , 1997, Electrophoresis.

[22]  L. Murphy,et al.  S100 proteins and their influence on pro-survival pathways in cancer. , 2004, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[23]  J. Carazo,et al.  GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists , 2007, Genome Biology.